Cytokines in symptomatic asthma airways

To determine whether cytokines are generated in vivo in subjects with asthma, we have measured cytokine (tumor necrosis factor [TNF], granulocyte-macrophage—colony-stimulating factor [GM—CSF], interleukin [IL]-1α, IL-1β, IL-2, IL-4, and IL-6) in the airways of subjects with symptomatic (N = 24) and...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 89; no. 5; pp. 958 - 967
Main Authors Broide, David H., Lotz, Martin, Cuomo, Anthony J., Coburn, David A., Federman, Edward C., Wasserman, Stephen I.
Format Journal Article
LanguageEnglish
Published New York, NY Mosby, Inc 01.05.1992
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To determine whether cytokines are generated in vivo in subjects with asthma, we have measured cytokine (tumor necrosis factor [TNF], granulocyte-macrophage—colony-stimulating factor [GM—CSF], interleukin [IL]-1α, IL-1β, IL-2, IL-4, and IL-6) in the airways of subjects with symptomatic (N = 24) and asymptomatic (N = 9) asthma with immunoassays (GM-CSF, IL-1α, IL-1β, IL-2, ad IL-4) or bioassays (TNF and IL-6) and the polymerase chain reaction (IL-1β and TNF). Significant levels of TNF (578 ± 917 pg/ml versus 24 ± 29 pg/ml) ( p = 0.01), GM-CSF (24 ± 41 pg/ml versus <8 pg/ml) ( p = 0.02), and IL-6 (225 ± 327 pg/ml versus 7 ± 12 pg/ml) ( p = 0.01), but not IL-1α or IL-4, were detected in the bronchoalveolar lavage fluid (BALF) of patients with symptomatic compared with BALF of patients with asymptomatic asthma. Levels of IL-1β (266 ± 270 pg/ml versus <20 pg/ml) ( p = 0.001) and IL-2 (1.4 ± 2.8 ng/ml versus <0.3 ng/ml) ( p = 0.05) in BALF in patients with asymptomatic compared with that in BALF levels in patients with asymptomatic asthma suggested activation of alveolar macrophages and T cells. Thus, in episodes of asthma, several cytokines, including TNF, GM-CSF, IL-1β, IL-2, and IL-6 are detectable in BALF.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0091-6749
1097-6825
DOI:10.1016/0091-6749(92)90218-Q